Background: Clozapine is the most effective drug for treatment-resistant schizophrenia, but its use is limited by toxicity. Because ethnicity has been reported to affect clozapine metabolism, we compared its steady state pharmacokinetics in New Zealand Maori and European patients. Methods: Clozapine and norclozapine steady state bioavailability was assessed over 24 h under fasting and fed conditions in 12 Maori and 16 European patients treated for chronic psychotic illnesses with stable once-daily clozapine doses. Plasma clozapine and norclozapine concentrations were assessed using liquid chromatography with tandem mass spectrometry; pharmacokinetic parameters were calculated using standard noncompartmental methods, and compared using unpaired t-tests. Findings: Mean pharmacokinetic parameters (AUC, C max and C min ) for clozapine and norclozapine were virtually identical in Maori and European subjects, under both fed and fasted conditions. Discussion: Clozapine bioavailability does not vary between Maori and European patients, and thus does not need to be considered in prescribing decisions. Additional studies are needed to identify if there are differences between Maori and European populations for drugs metabolized by other enzyme pathways.
Introduction
Compared with other antipsychotic drugs, clozapine is the most effective pharmacotherapy for schizophrenia; its use is generally restricted to treatment-resistant patients because of safety risks, notably agranulocytosis, myocarditis, and severe constipation (Barnes et al., 2011) . Surveys have identified similar (Wheeler et al., 2008) or somewhat higher (Dey et al., 2016) rates of clozapine use in Maori compared to Europeans, the two dominant ethnic groups in New Zealand. Ethnicity has been shown to influence clozapine pharmacokinetics in some settings; for example, compared with Caucasians, lower daily clozapine doses are needed to achieve comparable blood levels in Asian (Ng et al., 2005) and Mexican patients (González-Esquivel et al., 2011) . There are no published data on the pharmacokinetics of clozapine in Maori, although mean daily clozapine doses were similar in Maori and European patients in a retrospective cross-sectional survey (El-Badri and Mellsop, 2011) . Effective treatment of schizophrenia in Maori is of particular importance given its apparently higher prevalence compared with the European population (Kake et al., 2008) . This study used data from a bioequivalence trial of two clozapine formulations (Glue et al., 2012) in order to compare the pharmacokinetics of clozapine and its active metabolite norclozapine in Maori and European patients.
Materials and Methods
A detailed description of the bioequivalence study, including sample size calculation, is provided elsewhere (Glue et al., 2012) . In brief, the study enrolled 30 male and female subjects, aged 18 to 55 years, established on stable doses of clozapine for at least 3 months. Subjects were required to have a body mass index (BMI) between 18 and 35 kg/m 2 , and be in good health. Clozapine was prescribed in multiples of 50 mg, taken as a single evening dose. Subjects provided written informed consent prior to participation. The study conformed to standards indicated by the Declaration of Helsinki; approval was provided by the New Zealand Multi-Region Ethics Committee (MEC/10/09/094). The study design involved an 11-day dosing period with one formulation, tablet or suspension, with pharmacokinetic blood sampling under fasting and fed conditions on days 10 and 11, respectively. Study subjects were then switched to the alternate formulation from days 12-22, with repeated pharmacokinetic sampling on days 21 and EBioMedicine 27 (2018) 134-137
Abbreviations: C max , maximum plasma concentration; AUC 0 − τ , area under the curve from time 0 to the end of the dosing interval; t max , time to C max ; C min , minimum plasma concentration.
⁎ 22. The order in which formulations were administered was based on a computer-generated random code. The formulations were found to be bioequivalent under fasting and fed conditions (Glue et al., 2012) . This report describes the pharmacokinetics of the tablet formulation (Clozaril®, Novartis) in Maori and European participants.
On Days 10 and 21, subjects were admitted to the study clinic at least 10 h prior to drug administration, and were discharged after the final blood draw in the morning of Days 12 and 23. Clozapine was administered after an 8-hour fast on Days 10 and 21, and was dosed under fed conditions on Days 11 and 22 after consumption of a standardized high-fat meal (Food and Drug Administration, 2002) . All clozapine doses were administered with 240 mL water. There was no washout period between the two treatment periods. On Days 10, 11, 21 and 22, blood samples were collected at baseline and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 14, 16, 20 and 24 h after dosing. Following centrifugation, plasma samples were stored in polypropylene tubes at 70°C until assayed using validated liquid chromatography with tandem mass spectrometry methods. Clozapine was assayed using a previously reported method (Glue et al., 2012) . The norclozapine assay was similar although a different internal standard (N-desmethylmirtazapine) was used.
Pharmacokinetic parameters, calculated using standard noncompartmental methods, included maximum plasma concentration (C max ), area under the plasma concentration-time curve from time 0 to the end of the dosing interval (AUC 0-τ ), time to C max (t max ), and minimum concentration (C min ). Because patients were taking different daily doses of clozapine, all clozapine and norclozapine plasma concentrations and pharmacokinetic data were normalised to a dose of 100 mg. Safety was monitored by assessing adverse events, laboratory test results, vital signs (heart rate and blood pressure), and electrocardiograms (ECGs).
Pharmacokinetic parameters were compared using unpaired t-tests or, as necessary, the Mann-Whitney U test, a non-parametric equivalent. Safety data were analysed using summary statistics. The sample size for the study was pragmatic. Post-hoc assessment of statistical power indicates that the study had at least 80% power to detect a 40% difference in AUC and a 30% difference in C max , based on fasted pharmacokinetic parameters.
Results

Subjects
Of 30 subjects in the original bioequivalence study, two of other ethnic origins were excluded from the present comparison of 16 European (13 male, 3 female) with 12 Maori participants (10 male, 2 female), see Table 1 . Maori ethnicity was determined according to the New Zealand Census procedure (2001) , and confirmed by participants identifying at least one (mean 2.9, range 1-4) Maori grandparent. Neither age nor BMI differed statistically between the two groups (European [mean ± standard deviation] age = 38.0 ± 9.0 years, BMI = 30.0 ± 5.0 kg/m 2 ; Maori age = 37.6 ± 10.4 years, BMI = 32.2 ± 5.2 kg/m 2 ). Among
European participants there were 6 smokers and 10 nonsmokers, and in Maori, 8 smokers and 4 nonsmokers. The greater proportion of Maori than European smokers (67% vs. 37%) did not reach statistical significance (chi square = 1.31, p = 0.25).
Pharmacokinetics
Steady-state clozapine and norclozapine pharmacokinetic parameters are shown in Tables 2 and 3 . There were no statistically significant differences between Maori and European groups for any pharmacokinetic parameter, under both fed and fasted conditions. A 2-way analysis of variance indicated no significant effects of smoking, ethnicity, or their interaction on clozapine dose or pharmacokinetic parameters (data not shown).
Safety
There were no deaths or serious adverse events during the study. A total of 165 adverse events were reported by 18 subjects while taking clozapine tablets. The most common of these were drowsiness (46 reports), constipation (25 reports), dizziness (23 reports), dry mouth (16 reports), and confusion and blurred vision (15 reports each). All adverse events were of mild to moderate intensity. There were no differences in adverse event reporting between Maori and European groups, and all adverse events had resolved by study completion. There were no findings of note from safety laboratory tests, ECGs or vital signs.
Discussion
The main finding of this study is that there are no differences in steady-state clozapine or norclozapine pharmacokinetics, under both fed and fasted conditions, between Maori and NZ European patients. This finding is consistent with an earlier report of similar mean daily clozapine doses in Maori and European patients (El-Badri and Mellsop, 2011) .
Based on the complexity of clozapine metabolism, it was not possible a priori to predict whether Maori and European pharmacokinetic parameters would be similar or different. Cytochrome-P450 (CYP) 1A2 is the predominant enzyme involved in clozapine metabolism, with CYP3A and CYP2C19 also involved (Jaquenoud Sirot et al., 2009) . Maori have been reported to have higher frequencies of two poor metabolizer alleles for CYP2C19 (*2 and *3) compared with Caucasians (Lea et al., 2008) . Because of the substantial effects of environmental factors on CYP1A2 activity, phenotyping may be preferred for assessment of activity in vivo (Faber et al., 2005) . Rates of CYP1A2 poor metabolism vary by ethnic group (McGraw and Waller, 2012) , but there are as yet no published data available regarding Maori.
The limitations of this study include the fact that it was based on a post-hoc analysis of participants enrolled in a bioequivalence study. Although the entire study was adequately statistically powered, analysis by ethnic subgroup was not. Post-hoc estimates indicate the study was adequately powered to detect large (30-40%) differences in pharmacokinetic parameters, and thus subtle differences might be missed. On the other hand, the between group results are remarkably similar, suggesting that the risk of a Type II error is small. A further limitation of this study is that we were unable to control for smoking status or prescription of concomitant medications, both known to potentially affect clozapine metabolism.
In conclusion, the finding of essentially identical clozapine bioavailability in Maori and European subjects suggests that this drug can be dosed in the New Zealand setting without consideration of ethnicity.
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